Accolate Clinical Trials and Studies
Buy AccolateAccolate Information
Accolate Clinical Trials and Studies
Three U.S. double-blind, randomized, placebo-controlled, 13-week Accolate clinical trials in 1380 patients with mild-to-moderate asthma demonstrated that zafirlukast improved daytime asthma symptoms, nighttime awakenings, mornings with asthma symptoms, rescue beta2-agonist use, FEV1, and morning peak expiratory flow rate. In these Accolate studies, the patients had a mean baseline FEV1 of approximately 75% of predicted normal and a mean baseline beta-agonist requirement of approximately 4-5 puffs of albuterol per day.
In a second and smaller Accolate study, the effect of zafirlukast on most efficacy parameters was comparable to the active control (inhaled cromolyn sodium 1600 mcg 4 times per day) and superior to placebo at endpoint for decreasing rescue beta-agonist use.
In these trials, improvement in astma symptoms occurred within one week of initiating treatment with Accolate. The role of zafirlukast in the management of patients with more severe asthma, patients receiving antiasthma therapy other than as-needed, inhaled beta2-agonists, or as an oral or inhaled corticosteroid-sparing agent remains to be fully characterized.
Buy Accolate